CU20120118A7 - Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak - Google Patents
Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jakInfo
- Publication number
- CU20120118A7 CU20120118A7 CU2012000118A CU20120118A CU20120118A7 CU 20120118 A7 CU20120118 A7 CU 20120118A7 CU 2012000118 A CU2012000118 A CU 2012000118A CU 20120118 A CU20120118 A CU 20120118A CU 20120118 A7 CU20120118 A7 CU 20120118A7
- Authority
- CU
- Cuba
- Prior art keywords
- src
- inhibitors
- jak
- present
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000009977 dual effect Effects 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 102000038012 SFKs Human genes 0.000 abstract 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 abstract 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 102000001332 SRC Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003831 deregulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108010087686 src-Family Kinases Proteins 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos bicíclicos aromáticos sustituidos que contienen anillos de pirimidina y piridina así como también sales aceptables para uso farmacéuticos de los mismos.Los compuestos de la presente invención son útiles como inhibidores de la tirosina quinasa, con preferencia inhibidores de la familia SRC de las quinasas( SFK), en particular como inhibidores múltiples de la SFK/JAK quinasas e incluso, con preferencia, como inhibidores duales de las c- SRC/JAK quinasas, inhibiendo así la activación de STAT3 y, por lo tanto, el crecimiento anormal de los tipos celulares particulares.Notablemente, los compuestos de la presente invención son útiles para el tratamiento o inhibición de ciertas enfermedades que son el resultado de la desregulación de STAT3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN415CH2010 | 2010-02-17 | ||
| PCT/IB2011/050669 WO2011101806A1 (en) | 2010-02-17 | 2011-02-17 | Bicyclic compounds and their uses as dual c-src / jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20120118A7 true CU20120118A7 (es) | 2012-10-15 |
Family
ID=43903941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000118A CU20120118A7 (es) | 2010-02-17 | 2012-08-15 | Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8440679B2 (es) |
| EP (1) | EP2536722B1 (es) |
| JP (1) | JP2013519725A (es) |
| KR (1) | KR20120130294A (es) |
| CN (1) | CN102858770A (es) |
| AR (1) | AR089641A1 (es) |
| AU (1) | AU2011216895B2 (es) |
| BR (1) | BR112012020639A2 (es) |
| CA (1) | CA2789655A1 (es) |
| CU (1) | CU20120118A7 (es) |
| CY (1) | CY1115420T1 (es) |
| DK (1) | DK2536722T3 (es) |
| EA (1) | EA201290757A1 (es) |
| ES (1) | ES2470190T3 (es) |
| HR (1) | HRP20140437T1 (es) |
| IL (1) | IL221487A (es) |
| MX (1) | MX2012009482A (es) |
| NZ (1) | NZ602271A (es) |
| PH (1) | PH12012501654A1 (es) |
| PL (1) | PL2536722T3 (es) |
| PT (1) | PT2536722E (es) |
| RS (1) | RS53458B (es) |
| SA (1) | SA111320200B1 (es) |
| SG (1) | SG183329A1 (es) |
| SI (1) | SI2536722T1 (es) |
| SM (1) | SMT201400090B (es) |
| TW (1) | TW201130838A (es) |
| WO (1) | WO2011101806A1 (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013138393A1 (en) | 2012-03-12 | 2013-09-19 | Allergan, Inc. | Method of treating ophthalmic conditions with kinase inhibitors |
| EP2825537B1 (en) | 2012-03-12 | 2017-01-04 | Allergan, Inc. | Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10562912B2 (en) * | 2013-06-05 | 2020-02-18 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US9321766B1 (en) | 2014-10-06 | 2016-04-26 | Allergan, Inc. | Kinase inhibitors |
| US9296747B1 (en) | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| WO2017015367A1 (en) | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| CN107459519A (zh) * | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| WO2018222917A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| CN109336868A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 吲哚类stat3抑制剂及其制备方法 |
| CN109180657A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Stat3抑制剂的制备方法 |
| CN109293641A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴类stat3抑制剂及其制备方法 |
| CN109485643A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴酮类stat3抑制剂及制备方法与应用 |
| CN109369627A (zh) * | 2018-10-31 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 芴酮类stat3抑制剂晶型a及制备方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| WO2026117094A1 (ko) * | 2024-11-29 | 2026-06-04 | (주)파로스아이바이오 | 피리도[3,4-d]피리미딘-8-온 유도체의 폐암 예방, 개선 또는 치료 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4349472A (en) | 1979-04-27 | 1982-09-14 | Schering Corporation | (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| BR0116493A (pt) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| WO2005034869A2 (en) * | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1981886B1 (en) * | 2006-01-31 | 2009-08-12 | F.Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| WO2008077062A2 (en) | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression of stat3 reactivation after src kinase inhibition to treat cancer |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| JP2011500806A (ja) | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
-
2011
- 2011-02-16 SA SA111320200A patent/SA111320200B1/ar unknown
- 2011-02-17 ES ES11709484.7T patent/ES2470190T3/es active Active
- 2011-02-17 DK DK11709484.7T patent/DK2536722T3/da active
- 2011-02-17 PL PL11709484T patent/PL2536722T3/pl unknown
- 2011-02-17 RS RS20140277A patent/RS53458B/sr unknown
- 2011-02-17 PT PT117094847T patent/PT2536722E/pt unknown
- 2011-02-17 JP JP2012553436A patent/JP2013519725A/ja not_active Ceased
- 2011-02-17 WO PCT/IB2011/050669 patent/WO2011101806A1/en not_active Ceased
- 2011-02-17 NZ NZ602271A patent/NZ602271A/xx not_active IP Right Cessation
- 2011-02-17 CN CN2011800165418A patent/CN102858770A/zh active Pending
- 2011-02-17 CA CA2789655A patent/CA2789655A1/en not_active Abandoned
- 2011-02-17 AR ARP110100492A patent/AR089641A1/es unknown
- 2011-02-17 BR BR112012020639A patent/BR112012020639A2/pt not_active IP Right Cessation
- 2011-02-17 EA EA201290757A patent/EA201290757A1/ru unknown
- 2011-02-17 SG SG2012060489A patent/SG183329A1/en unknown
- 2011-02-17 AU AU2011216895A patent/AU2011216895B2/en not_active Expired - Fee Related
- 2011-02-17 SI SI201130155T patent/SI2536722T1/sl unknown
- 2011-02-17 HR HRP20140437AT patent/HRP20140437T1/hr unknown
- 2011-02-17 TW TW100105192A patent/TW201130838A/zh unknown
- 2011-02-17 PH PH1/2012/501654A patent/PH12012501654A1/en unknown
- 2011-02-17 EP EP11709484.7A patent/EP2536722B1/en not_active Not-in-force
- 2011-02-17 US US13/578,656 patent/US8440679B2/en not_active Expired - Fee Related
- 2011-02-17 KR KR1020127023889A patent/KR20120130294A/ko not_active Withdrawn
- 2011-02-17 MX MX2012009482A patent/MX2012009482A/es active IP Right Grant
-
2012
- 2012-08-15 IL IL221487A patent/IL221487A/en not_active IP Right Cessation
- 2012-08-15 CU CU2012000118A patent/CU20120118A7/es unknown
-
2013
- 2013-01-14 US US13/741,019 patent/US8962637B2/en not_active Expired - Fee Related
-
2014
- 2014-06-03 CY CY20141100393T patent/CY1115420T1/el unknown
- 2014-07-10 SM SM201400090T patent/SMT201400090B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2536722T3 (da) | 2014-05-26 |
| US20130012518A1 (en) | 2013-01-10 |
| EP2536722A1 (en) | 2012-12-26 |
| AU2011216895A1 (en) | 2012-09-27 |
| CY1115420T1 (el) | 2017-01-04 |
| NZ602271A (en) | 2013-09-27 |
| US20130143895A1 (en) | 2013-06-06 |
| CA2789655A1 (en) | 2011-08-25 |
| AU2011216895B2 (en) | 2015-11-05 |
| EP2536722B1 (en) | 2014-04-16 |
| WO2011101806A1 (en) | 2011-08-25 |
| EA201290757A1 (ru) | 2013-04-30 |
| TW201130838A (en) | 2011-09-16 |
| IL221487A (en) | 2014-11-30 |
| KR20120130294A (ko) | 2012-11-30 |
| SG183329A1 (en) | 2012-09-27 |
| JP2013519725A (ja) | 2013-05-30 |
| RS53458B (sr) | 2014-12-31 |
| MX2012009482A (es) | 2012-11-29 |
| PT2536722E (pt) | 2014-05-26 |
| US8962637B2 (en) | 2015-02-24 |
| PL2536722T3 (pl) | 2014-11-28 |
| CN102858770A (zh) | 2013-01-02 |
| ES2470190T3 (es) | 2014-06-23 |
| AR089641A1 (es) | 2014-09-10 |
| PH12012501654A1 (en) | 2018-02-07 |
| HRP20140437T1 (hr) | 2014-08-29 |
| BR112012020639A2 (pt) | 2017-08-08 |
| SA111320200B1 (ar) | 2014-02-16 |
| US8440679B2 (en) | 2013-05-14 |
| SI2536722T1 (sl) | 2014-10-30 |
| SMT201400090B (it) | 2014-09-08 |
| HK1178897A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012020639A2 (pt) | compostos biciclicos e seus usos como duplo inibidores de c-src/jak. | |
| CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| DOP2014000188A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| CR11650A (es) | DERIVADOS BICICLICOS HETEROCICLICOS O ESPIROBICICLICOS HETEROCICLICOS ENLAZADOS, DE PIRAZOLO[1,5-a] PIRIMIDINAS, PROCEDIMIENTOS PARA SU PREPARACION Y USOS DE LOS MISMOS | |
| MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| MX361815B (es) | Compuestos pirazolopirimidinicos como inhibidores de cinasas. | |
| UY35249A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| MX2019003468A (es) | Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. | |
| UY31821A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| BR112015019508A8 (pt) | formas sólidas de um inibidor de cdk4/6 seletivo | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| CR20140031A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| PA8834001A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
| NI201200029A (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CO6680703A2 (es) | Derivados de 6,7-dihidro-3h-oxazolo(3,4-a)pirazin-5,8-diona | |
| CU20140107A7 (es) | Derivados macrocíclicos para el tratamiento de enfermedades |